SK285669B6 - Ekteinascidínová zlúčenina, farmaceutický prostriedok s jej obsahom a jej použitie - Google Patents
Ekteinascidínová zlúčenina, farmaceutický prostriedok s jej obsahom a jej použitie Download PDFInfo
- Publication number
- SK285669B6 SK285669B6 SK1501-2000A SK15012000A SK285669B6 SK 285669 B6 SK285669 B6 SK 285669B6 SK 15012000 A SK15012000 A SK 15012000A SK 285669 B6 SK285669 B6 SK 285669B6
- Authority
- SK
- Slovakia
- Prior art keywords
- mammalian
- ecteinascidin
- iso
- ecteinascidin compound
- fab
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 229960000977 trabectedin Drugs 0.000 title claims description 12
- -1 Ecteinascidin compound Chemical class 0.000 title claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 201000001441 melanoma Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 208000032839 leukemia Diseases 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical class C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 abstract description 16
- 201000005296 lung carcinoma Diseases 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000798369 Ecteinascidia turbinata Species 0.000 description 2
- 241000737281 Isoetes Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- RBZMSGOBSOCYHR-UHFFFAOYSA-N 1,4-bis(bromomethyl)benzene Chemical group BrCC1=CC=C(CBr)C=C1 RBZMSGOBSOCYHR-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000002044 Rhizophora apiculata Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 101150114218 allB gene Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pyrane Compounds (AREA)
- Peptides Or Proteins (AREA)
- Furan Compounds (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8080298P | 1998-04-06 | 1998-04-06 | |
| PCT/US1999/007471 WO1999051238A1 (en) | 1998-04-06 | 1999-04-05 | Semi-synthetic ecteinascidins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK15012000A3 SK15012000A3 (sk) | 2001-08-06 |
| SK285669B6 true SK285669B6 (sk) | 2007-06-07 |
Family
ID=22159716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1501-2000A SK285669B6 (sk) | 1998-04-06 | 1999-04-05 | Ekteinascidínová zlúčenina, farmaceutický prostriedok s jej obsahom a jej použitie |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6124293A (cs) |
| EP (2) | EP1067933B1 (cs) |
| JP (1) | JP4443043B2 (cs) |
| KR (1) | KR100603219B1 (cs) |
| CN (1) | CN1157189C (cs) |
| AT (1) | ATE370148T1 (cs) |
| AU (1) | AU758100B2 (cs) |
| BG (1) | BG65088B1 (cs) |
| BR (1) | BR9909488B1 (cs) |
| CA (1) | CA2327468C (cs) |
| CY (1) | CY1106988T1 (cs) |
| CZ (1) | CZ301083B6 (cs) |
| DE (1) | DE69936845T2 (cs) |
| DK (1) | DK1067933T3 (cs) |
| ES (1) | ES2292237T3 (cs) |
| HU (1) | HUP0104273A3 (cs) |
| IL (2) | IL138856A0 (cs) |
| MX (1) | MXPA00009840A (cs) |
| NO (1) | NO328147B1 (cs) |
| NZ (1) | NZ507350A (cs) |
| PL (1) | PL196809B1 (cs) |
| PT (1) | PT1067933E (cs) |
| RU (1) | RU2217432C2 (cs) |
| SK (1) | SK285669B6 (cs) |
| TR (1) | TR200002921T2 (cs) |
| UA (1) | UA59439C2 (cs) |
| WO (1) | WO1999051238A1 (cs) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| CA2331593C (en) * | 1998-05-11 | 2008-08-05 | Pharma Mar, S.A. | Metabolites of ecteinascidin 743 |
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| AR035842A1 (es) * | 1999-05-14 | 2004-07-21 | Pharma Mar Sa | Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo |
| US6686470B2 (en) | 2000-01-19 | 2004-02-03 | The Trustees Of Columbia University In The City Of New York | Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof |
| US7919493B2 (en) * | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
| MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| US6809099B2 (en) | 2000-11-03 | 2004-10-26 | President And Fellows Of Harvard College | Saframycins, analogues and uses thereof |
| SK287901B6 (sk) * | 2000-11-06 | 2012-03-02 | Pharma Mar, S. A. | Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment |
| GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| GB0202544D0 (en) * | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
| GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
| PL1689404T3 (pl) | 2003-11-13 | 2009-02-27 | Pharma Mar Sau | Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka |
| GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| US20080255132A1 (en) * | 2003-11-14 | 2008-10-16 | Eric Rowinsky | Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer |
| EP1768671A2 (en) * | 2004-07-09 | 2007-04-04 | Pharma Mar, S.A. | Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
| JP2008514688A (ja) * | 2004-09-29 | 2008-05-08 | ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル | 抗炎症剤としてのエクテイナシジン化合物 |
| SI1827500T1 (sl) * | 2004-10-26 | 2009-10-31 | Pharma Mar Sa | Pegiliran liposomski doksorubicin v kombinaciji s ekteinescidinom 743 |
| RS50510B (sr) | 2004-10-29 | 2010-03-02 | Pharma Mar S.A., Sociedad Unipersonal | Formulacije koje sadrže ekteinascidin i disaharid |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| CN100355775C (zh) * | 2006-01-20 | 2007-12-19 | 南方医科大学 | 一种海鞘多肽及其制备方法 |
| AU2008313634A1 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Prognostic molecular markers for ET-743 treatment |
| CA2995033C (en) | 2010-11-12 | 2020-04-28 | Pharma Mar, S.A. | Combination therapy with an antitumor alkaloid |
| KR20180103965A (ko) * | 2016-02-04 | 2018-09-19 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 위장관 외용을 위한 트라벡테딘-함유 주사가능한 약학적 조성물 및 그의 제조 방법 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| IL293128A (en) | 2019-11-21 | 2022-07-01 | Pharma Mar Sa | Methods of treating small cell lung cancer with lurbinectedin formulations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| US5089273A (en) * | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| US5149804A (en) * | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| TW221441B (cs) * | 1991-01-25 | 1994-03-01 | Taiho Pharmaceutical Co Ltd | |
| US5440055A (en) * | 1993-03-12 | 1995-08-08 | Aphios Corporation | Method and apparatus for extracting taxol from source materials |
| US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
-
1999
- 1999-04-05 EP EP99916379A patent/EP1067933B1/en not_active Expired - Lifetime
- 1999-04-05 MX MXPA00009840A patent/MXPA00009840A/es active IP Right Grant
- 1999-04-05 US US09/286,242 patent/US6124293A/en not_active Expired - Fee Related
- 1999-04-05 PL PL343439A patent/PL196809B1/pl not_active IP Right Cessation
- 1999-04-05 DK DK99916379T patent/DK1067933T3/da active
- 1999-04-05 AU AU34713/99A patent/AU758100B2/en not_active Ceased
- 1999-04-05 CZ CZ20003650A patent/CZ301083B6/cs not_active IP Right Cessation
- 1999-04-05 DE DE69936845T patent/DE69936845T2/de not_active Expired - Lifetime
- 1999-04-05 IL IL13885699A patent/IL138856A0/xx active IP Right Grant
- 1999-04-05 TR TR2000/02921T patent/TR200002921T2/xx unknown
- 1999-04-05 CN CNB998070769A patent/CN1157189C/zh not_active Expired - Fee Related
- 1999-04-05 JP JP2000542009A patent/JP4443043B2/ja not_active Expired - Fee Related
- 1999-04-05 CA CA002327468A patent/CA2327468C/en not_active Expired - Fee Related
- 1999-04-05 NZ NZ507350A patent/NZ507350A/xx unknown
- 1999-04-05 KR KR1020007011112A patent/KR100603219B1/ko not_active Expired - Fee Related
- 1999-04-05 WO PCT/US1999/007471 patent/WO1999051238A1/en active IP Right Grant
- 1999-04-05 SK SK1501-2000A patent/SK285669B6/sk not_active IP Right Cessation
- 1999-04-05 AT AT99916379T patent/ATE370148T1/de not_active IP Right Cessation
- 1999-04-05 EP EP07011035A patent/EP1876180A3/en not_active Withdrawn
- 1999-04-05 BR BRPI9909488-6A patent/BR9909488B1/pt not_active IP Right Cessation
- 1999-04-05 ES ES99916379T patent/ES2292237T3/es not_active Expired - Lifetime
- 1999-04-05 PT PT99916379T patent/PT1067933E/pt unknown
- 1999-04-05 RU RU2000128058/04A patent/RU2217432C2/ru not_active IP Right Cessation
- 1999-04-05 HU HU0104273A patent/HUP0104273A3/hu unknown
- 1999-05-04 UA UA2000105674A patent/UA59439C2/uk unknown
-
2000
- 2000-10-03 NO NO20004978A patent/NO328147B1/no not_active IP Right Cessation
- 2000-10-04 IL IL138856A patent/IL138856A/en not_active IP Right Cessation
- 2000-11-02 BG BG104902A patent/BG65088B1/bg unknown
-
2007
- 2007-11-08 CY CY20071101439T patent/CY1106988T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK285669B6 (sk) | Ekteinascidínová zlúčenina, farmaceutický prostriedok s jej obsahom a jej použitie | |
| CA2457056C (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor | |
| JP2010540471A (ja) | ガンボギン酸グリコシド誘導体及びアナログ、並びにその製法及び応用 | |
| EP2824108B1 (en) | Tetracyclic anthraquinone derivatives | |
| JPH10506410A (ja) | 抗腫瘍剤及び抗ウイルス剤としてのビス−（２−ハロエチル）アミノフェニル置換ジスタマイシン誘導体 | |
| HU217630B (hu) | 3'-Aziridino-antraciklin-származékok, eljárás ezek előállítására és e vegyületeket tartalmazó gyógyászati készítmények | |
| ES2339152T3 (es) | Dimeros halogenados de quindolina para el tratamiento del cancer. | |
| JPH05247001A (ja) | 置換ベンゾイルウレア誘導体又はその塩、それらの製造方法及びそれらを含有する抗癌剤 | |
| FI61187B (fi) | Foerfarande foer framstaellning av antitumoera 1,2-5,6-dianhydro-3,4-di-0-acylgalaktitolderivat | |
| KR100390767B1 (ko) | 아지리디닐퀴놀린디온 유도체와 그의 제조방법 | |
| KR102162351B1 (ko) | 약물-결합 화합물 및 이의 용도 | |
| HK1033651B (en) | Semi-synthetic ecteinascidins | |
| HU206087B (en) | Process for producing n-acylated derivatives of 9,10-anthracene-dicarboxaldehyde-bis(2-imidazolin-2-yl-hydrazole) and pharmaceutical compositions comprising same as active ingredient | |
| JPH0834788A (ja) | ピロロベンゾカルバゾール誘導体及びその製造方法 | |
| KR20180015266A (ko) | 스테로이드성 락탐 및 비스(2-클로로에틸)아미노페녹시 프로피온산 유도체의 에스테르 | |
| JPH08151379A (ja) | ビス（ピロロインドール）誘導体及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20110405 |